These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10544220)

  • 1. Expression of the neurofibromatosis type 2 gene in human tissues.
    den Bakker MA; Vissers KJ; Molijn AC; Kros JM; Zwarthoff EC; van der Kwast TH
    J Histochem Cytochem; 1999 Nov; 47(11):1471-80. PubMed ID: 10544220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Widespread but cell type-specific expression of the mouse neurofibromatosis type 2 gene.
    Claudio JO; Lutchman M; Rouleau GA
    Neuroreport; 1995 Oct; 6(14):1942-6. PubMed ID: 8547603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of neurofibromatosis 2 transcript and gene product during mouse fetal development.
    Huynh DP; Tran TM; Nechiporuk T; Pulst SM
    Cell Growth Differ; 1996 Nov; 7(11):1551-61. PubMed ID: 8930405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells.
    Scherer SS; Gutmann DH
    J Neurosci Res; 1996 Dec; 46(5):595-605. PubMed ID: 8951671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome?
    Kley N; Seizinger BR
    Cancer Surv; 1995; 25():207-18. PubMed ID: 8718520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mouse homologue of the neurofibromatosis type 2 gene is highly conserved.
    Claudio JO; Marineau C; Rouleau GA
    Hum Mol Genet; 1994 Jan; 3(1):185-90. PubMed ID: 8162023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
    Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
    Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interdomain binding mediates tumor growth suppression by the NF2 gene product.
    Sherman L; Xu HM; Geist RT; Saporito-Irwin S; Howells N; Ponta H; Herrlich P; Gutmann DH
    Oncogene; 1997 Nov; 15(20):2505-9. PubMed ID: 9395247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases.
    Maxwell M; Shih SD; Galanopoulos T; Hedley-Whyte ET; Cosgrove GR
    J Neurosurg; 1998 Mar; 88(3):562-9. PubMed ID: 9488313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants.
    Wellenreuther R; Waha A; Vogel Y; Lenartz D; Schramm J; Wiestler OD; von Deimling A
    Lab Invest; 1997 Dec; 77(6):601-6. PubMed ID: 9426397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the neurofibromatosis 2 gene promoter expression during embryonic development.
    Akhmametyeva EM; Mihaylova MM; Luo H; Kharzai S; Welling DB; Chang LS
    Dev Dyn; 2006 Oct; 235(10):2771-85. PubMed ID: 16894610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.
    Kley N; Whaley J; Seizinger BR
    Glia; 1995 Nov; 15(3):297-307. PubMed ID: 8586465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain.
    Gong JP; Onaivi ES; Ishiguro H; Liu QR; Tagliaferro PA; Brusco A; Uhl GR
    Brain Res; 2006 Feb; 1071(1):10-23. PubMed ID: 16472786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
    Sirén V; Antinheimo JP; Jääskeläinen J; Böhling T; Carpén O; Vaheri A
    Acta Neurochir (Wien); 2004 Feb; 146(2):111-8. PubMed ID: 14963743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neurofibromatosis type 2 (NF2)].
    Araki N; Takeshima H; Saya H
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a cytoskeleton attachment domain at the N-terminus of the NF2 protein.
    den Bakker MA; Riegman PH; Suurmeijer AP; Vissers CJ; Sainio M; Carpen O; Zwarthoff EC
    J Neurosci Res; 2000 Dec; 62(6):764-71. PubMed ID: 11107160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of NF2 gene deletion in pediatric meningiomas using chromogenic in situ hybridization.
    Begnami MD; Rushing EJ; Santi M; Quezado M
    Int J Surg Pathol; 2007 Apr; 15(2):110-5. PubMed ID: 17478763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF2: the wizardry of merlin.
    Xiao GH; Chernoff J; Testa JR
    Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential gene expression between human schwannoma and control Schwann cells.
    Hanemann CO; Bartelt-Kirbach B; Diebold R; Kämpchen K; Langmesser S; Utermark T
    Neuropathol Appl Neurobiol; 2006 Dec; 32(6):605-14. PubMed ID: 17083475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.
    Koga H; Araki N; Takeshima H; Nishi T; Hirota T; Kimura Y; Nakao M; Saya H
    Oncogene; 1998 Aug; 17(7):801-10. PubMed ID: 9779996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.